SAG
SLN

SageView Advisory Group’s Silence Therapeutics SLN Stock Holding History

SageView Advisory Group’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$67 Buy
+11
New +$70 ﹤0.01% 2558

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

SageView Advisory Group's SLN Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Silence Therapeutics (SLN) in Q4 2025: 11 shares worth $67. The stake represents ﹤0.01% of the portfolio and ranks #2558 among its holdings.

58 funds tracked by Wall St. Rank hold SLN as of Q4 2025.

  • SageView Advisory Group held 11 shares of Silence Therapeutics worth $67 as of Q4 2025.
  • Silence Therapeutics was a new SageView Advisory Group position in Q4 2025.
  • Silence Therapeutics made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2558 holding.
  • 58 funds tracked by Wall St. Rank held Silence Therapeutics as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.